Objective To explore the risk management of the changes of sponsors and/or production sites during drug clinical trials based on the theories of quality management,risk management,and change management.Methods The met...Objective To explore the risk management of the changes of sponsors and/or production sites during drug clinical trials based on the theories of quality management,risk management,and change management.Methods The method of failure modes and effect analysis(FMEA)was used to identify risks through literature research,expert consultation,comparative research,and comprehensive analysis.Besides,risk priority number(RPN)was used to evaluate the risks.Results and Conclusion A FMEA of the changes of sponsors and/or production sites in clinical trials was constructed and RPN values of every failure mode and causes were obtained.Based on the RPN values,the core risk control points for different combination modes of sponsors and/or production sites after their changes were identified.It is recommended that China should strengthen the construction of the sponsor responsibility system.In addition,the changes of sponsors and/or production sites during the clinical trial period should be allowed in an orderly manner under the premise of ensuring the quality of clinical trials and subject protection.展开更多
Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bo...Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bouvier Tel:0043 4262 505 570 Fax:0043 4262展开更多
Chinese Society of Rare Earths Vicarious Director General： Mr. Gan Yong Tel： 86 10 62182748 Fax： 86 10 62173501 Treibacher Zndustrle AG CEO： Mr. Reinhard Iro COO： Mr. Alexander Bouvier Tel：0043 4262 505 570...Chinese Society of Rare Earths Vicarious Director General： Mr. Gan Yong Tel： 86 10 62182748 Fax： 86 10 62173501 Treibacher Zndustrle AG CEO： Mr. Reinhard Iro COO： Mr. Alexander Bouvier Tel：0043 4262 505 570 Fax：0043 4262 505 8570展开更多
Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bo...Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bouvier Tel:0043 4262 505 570 Fax:0043 4262 2898 AMR Technologies Inc. President: Peter V. Gundy Tel: 001 416 3678588 Fax: 001 416展开更多
Chinese Society of Rare EarthsDirector General: Prof. Bi QunTel: 86 10 62182748 Fax: 86 10 62173501Baotou Rare Earth HI-Tech Development ZoneDirector: Prof. Su WenqingTel: 86 472 5159784/5128065 Fax: 86 472 5156391 Ch...Chinese Society of Rare EarthsDirector General: Prof. Bi QunTel: 86 10 62182748 Fax: 86 10 62173501Baotou Rare Earth HI-Tech Development ZoneDirector: Prof. Su WenqingTel: 86 472 5159784/5128065 Fax: 86 472 5156391 China Rare Earth Holdings LimitedPresident: Jiang Quanlong Tel: 86 510 7456666 Fax: 86 510展开更多
The reigning world champion team joins hands with the express delivery service to greet the coming Olympics Starting this year, Olympic badminton champion Zhang Ning and world badminton champion Lin Dan will be wearin...The reigning world champion team joins hands with the express delivery service to greet the coming Olympics Starting this year, Olympic badminton champion Zhang Ning and world badminton champion Lin Dan will be wearing clothing with the FedEx logo on it.展开更多
Contrary to other markets where underwriters perform a combined role of underwriting and sponsoring in an Initial Public Offering(IPO),IPO issuers in Hong Kong must appoint at least one sponsor in addition to the unde...Contrary to other markets where underwriters perform a combined role of underwriting and sponsoring in an Initial Public Offering(IPO),IPO issuers in Hong Kong must appoint at least one sponsor in addition to the underwriters.The spitting of the single role of underwriters into two separate ones offers an ideal setting to disentangle the effects of the two roles and to examine which of the two roles-sponsor or underwriter--is more important in explaining IPO underpricing and initial volatility in the Hong Kong equity market.Interestingly,our findings provide supportive evidence that the sponsor reputation does matter in an IPO and it is even more significant than the underwriter reputation in explaining the IPO underpricing phenomenon.Given the recent high-tech fervor,our research goes deeper to examine specifically the role of sponsors on high-tech firms,with results indicating that the reliance on sponsors is higher for traditional isuers than for technology firms.We further discover that sponsors and underwriters are playing substitution roles rather than complementary roles.In order to examine the regulatory policy impact,our research also compares the role of IPO sponsors before and after the launch of the new sponsor regulatory regime in 2013.The empirical findings lend support to our argument that after the launch of the new regulations,public awareness of sponsors is raised,respect towards more reputable sponsor increases,and thus,the role of sponsors becomes more impotant than before.展开更多
Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical ...Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical University,sponsored by Shanxi Nursing Association and Shanxi Medical Periodical Press Co.,Ltd.Frontiers of Nursing has been indexed by databases including Scopus,Google Scholar,DOAJ,Baidu Scholar,CNKI,VIP,Wanfang,Chaoxing,and so on.展开更多
Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical ...Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical University,sponsored by Shanxi Nursing Association and Shanxi Medical Periodical Press Co.,Ltd.Frontiers of Nursing has been indexed by databases including Scopus,Google Scholar,DOAJ,Baidu Scholar,CNKI,VIP,Wanfang,Chaoxing,and so on.展开更多
Description Journa/of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by Chinese Association of Agr...Description Journa/of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by Chinese Association of Agricultural Science Societies(CAASS).JIA is a peer-reviewed and multi-disciplinary international journal and published monthly in English.JIA Editorial Board consists of 289 well-respected scholars of agricultural scientific fields.CAAS President,Academician Kongming Wu is the Chairman of the Board,and Academician Hualan Chen is the Editor-in-Chief.JIA has been available online at ScienceDirect since 2006 and is a leading academic journal in agricultural sciences in China.As released by JCR,the latest IF of the journal is 4.6.展开更多
Instruction to Authors Aims and Scope Journal of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by...Instruction to Authors Aims and Scope Journal of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by Chinsese Association of Agricultural Science Societies(CAAsS).展开更多
The concept of benefaction,as shaped in the pre-industrial society,has been altered and replaced by the modern term of sponsoring.The verbal transformation emerges from a deep cultural shift.Focusing on the dipole of ...The concept of benefaction,as shaped in the pre-industrial society,has been altered and replaced by the modern term of sponsoring.The verbal transformation emerges from a deep cultural shift.Focusing on the dipole of benefactionsponsoring,we examine the cultural transition from the traditional communities of long duration to the modern societies of consumption,taking the Greek mountainous regions as an example.We investigate the cultural shift that generates the metastasis from the communities of benefaction to the modern brandplaces that consume their own cultural heritage,mainly,at the altar of the tourism industry.Modern society has adopted the concept of sponsoring,for the grace of which,culture has to prove evidence of economic value,in order to survive.In the extremely competitive frame of the free-market economy,mountain regions appear vulnerable.The selling and buying of their culture are tempting and attractive under a constantly shrinking welfare-state and narrowing development opportunities.It depends on local and national society to rediscover and regenerate those social mechanisms able to create culture or let the modern consumption-oriented forces prevail.However,authentic principles of benefaction may form an alternative perspective for social reorganization.展开更多
Correct definition and management of sponsor- investigator relationship is of central importance for planing and executing clinical trials. During the last decade, there have been numerous modifications of guidelindes...Correct definition and management of sponsor- investigator relationship is of central importance for planing and executing clinical trials. During the last decade, there have been numerous modifications of guidelindes, international and national legislations and regulations. This implicated various alterations and shifts of essential responsibilities and tasks relating to the investigator, sponsor or sponsor-investigator what raised financial, clinical and ethical issues. First experiences with these new regulations and legislations are discussed together with international differences and their impacts on clinical trials. Regarding non-commercial trials and institutional sponsorship, there are still open organizational and legal questions after national implementation of the Europeam Clinical Trials Directive in 2004, although various approaches have been suggested in recent years in Europe. Current trends and controversies are discussed as well. A literature review was performed summarizing recent experiences with current legislations and risen controversies of these new legislations showing impact on future trends.展开更多
文摘Objective To explore the risk management of the changes of sponsors and/or production sites during drug clinical trials based on the theories of quality management,risk management,and change management.Methods The method of failure modes and effect analysis(FMEA)was used to identify risks through literature research,expert consultation,comparative research,and comprehensive analysis.Besides,risk priority number(RPN)was used to evaluate the risks.Results and Conclusion A FMEA of the changes of sponsors and/or production sites in clinical trials was constructed and RPN values of every failure mode and causes were obtained.Based on the RPN values,the core risk control points for different combination modes of sponsors and/or production sites after their changes were identified.It is recommended that China should strengthen the construction of the sponsor responsibility system.In addition,the changes of sponsors and/or production sites during the clinical trial period should be allowed in an orderly manner under the premise of ensuring the quality of clinical trials and subject protection.
文摘Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bouvier Tel:0043 4262 505 570 Fax:0043 4262
文摘Chinese Society of Rare Earths Vicarious Director General： Mr. Gan Yong Tel： 86 10 62182748 Fax： 86 10 62173501 Treibacher Zndustrle AG CEO： Mr. Reinhard Iro COO： Mr. Alexander Bouvier Tel：0043 4262 505 570 Fax：0043 4262 505 8570
文摘Chinese Society of Rare Earths Director General: Prof. Bi Qun Tel: 86 10 62182748 Fax: 86 10 62173501 Treibacher Industrie AG President: Mr. Reinhard Iro Managing Director Responsible For RE Business: Mr. Alexander Bouvier Tel:0043 4262 505 570 Fax:0043 4262 2898 AMR Technologies Inc. President: Peter V. Gundy Tel: 001 416 3678588 Fax: 001 416
文摘The reigning world champion team joins hands with the express delivery service to greet the coming Olympics Starting this year, Olympic badminton champion Zhang Ning and world badminton champion Lin Dan will be wearing clothing with the FedEx logo on it.
文摘Contrary to other markets where underwriters perform a combined role of underwriting and sponsoring in an Initial Public Offering(IPO),IPO issuers in Hong Kong must appoint at least one sponsor in addition to the underwriters.The spitting of the single role of underwriters into two separate ones offers an ideal setting to disentangle the effects of the two roles and to examine which of the two roles-sponsor or underwriter--is more important in explaining IPO underpricing and initial volatility in the Hong Kong equity market.Interestingly,our findings provide supportive evidence that the sponsor reputation does matter in an IPO and it is even more significant than the underwriter reputation in explaining the IPO underpricing phenomenon.Given the recent high-tech fervor,our research goes deeper to examine specifically the role of sponsors on high-tech firms,with results indicating that the reliance on sponsors is higher for traditional isuers than for technology firms.We further discover that sponsors and underwriters are playing substitution roles rather than complementary roles.In order to examine the regulatory policy impact,our research also compares the role of IPO sponsors before and after the launch of the new sponsor regulatory regime in 2013.The empirical findings lend support to our argument that after the launch of the new regulations,public awareness of sponsors is raised,respect towards more reputable sponsor increases,and thus,the role of sponsors becomes more impotant than before.
文摘Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical University,sponsored by Shanxi Nursing Association and Shanxi Medical Periodical Press Co.,Ltd.Frontiers of Nursing has been indexed by databases including Scopus,Google Scholar,DOAJ,Baidu Scholar,CNKI,VIP,Wanfang,Chaoxing,and so on.
文摘Frontiers of Nursing is a nursing academic journal,CN 14-1395/R,ISSN 2097-5368.Size A4,quarterly publication,color printing,public offerings at home and abroad which is managed by the First Hospital of Shanxi Medical University,sponsored by Shanxi Nursing Association and Shanxi Medical Periodical Press Co.,Ltd.Frontiers of Nursing has been indexed by databases including Scopus,Google Scholar,DOAJ,Baidu Scholar,CNKI,VIP,Wanfang,Chaoxing,and so on.
文摘Description Journa/of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by Chinese Association of Agricultural Science Societies(CAASS).JIA is a peer-reviewed and multi-disciplinary international journal and published monthly in English.JIA Editorial Board consists of 289 well-respected scholars of agricultural scientific fields.CAAS President,Academician Kongming Wu is the Chairman of the Board,and Academician Hualan Chen is the Editor-in-Chief.JIA has been available online at ScienceDirect since 2006 and is a leading academic journal in agricultural sciences in China.As released by JCR,the latest IF of the journal is 4.6.
文摘Instruction to Authors Aims and Scope Journal of Integrative Agriculture(JIA),formerly Agricultural Sciences in China(ASC),founded in 2002,is sponsored by Chinese Academy of Agricultural Sciences(CAAS),co-sponsored by Chinsese Association of Agricultural Science Societies(CAAsS).
文摘The concept of benefaction,as shaped in the pre-industrial society,has been altered and replaced by the modern term of sponsoring.The verbal transformation emerges from a deep cultural shift.Focusing on the dipole of benefactionsponsoring,we examine the cultural transition from the traditional communities of long duration to the modern societies of consumption,taking the Greek mountainous regions as an example.We investigate the cultural shift that generates the metastasis from the communities of benefaction to the modern brandplaces that consume their own cultural heritage,mainly,at the altar of the tourism industry.Modern society has adopted the concept of sponsoring,for the grace of which,culture has to prove evidence of economic value,in order to survive.In the extremely competitive frame of the free-market economy,mountain regions appear vulnerable.The selling and buying of their culture are tempting and attractive under a constantly shrinking welfare-state and narrowing development opportunities.It depends on local and national society to rediscover and regenerate those social mechanisms able to create culture or let the modern consumption-oriented forces prevail.However,authentic principles of benefaction may form an alternative perspective for social reorganization.
文摘Correct definition and management of sponsor- investigator relationship is of central importance for planing and executing clinical trials. During the last decade, there have been numerous modifications of guidelindes, international and national legislations and regulations. This implicated various alterations and shifts of essential responsibilities and tasks relating to the investigator, sponsor or sponsor-investigator what raised financial, clinical and ethical issues. First experiences with these new regulations and legislations are discussed together with international differences and their impacts on clinical trials. Regarding non-commercial trials and institutional sponsorship, there are still open organizational and legal questions after national implementation of the Europeam Clinical Trials Directive in 2004, although various approaches have been suggested in recent years in Europe. Current trends and controversies are discussed as well. A literature review was performed summarizing recent experiences with current legislations and risen controversies of these new legislations showing impact on future trends.
